These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1354 related articles for article (PubMed ID: 33853970)

  • 21. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutation profile of SARS-CoV-2 genome in a sample from the first year of the pandemic in Colombia.
    Gálvez JM; Chaparro-Solano HM; Pinzón-Rondón ÁM; Albornoz LL; Pardo-Oviedo JM; Zapata-Gómez FA; Patiño-Aldana AF; Hernández-Rodríguez ADP; Díaz-Quiroz M; Ruiz-Sternberg ÁM
    Infect Genet Evol; 2022 Jan; 97():105192. PubMed ID: 34933126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain).
    Andrés C; Piñana M; Borràs-Bermejo B; González-Sánchez A; García-Cehic D; Esperalba J; Rando A; Zules-Oña RG; Campos C; Codina MG; Blanco-Grau A; Colomer-Castell S; Martín MC; Castillo C; García-Comuñas K; Vásquez-Mercado R; Martins-Martins R; Saubi N; Campins-Martí M; Pumarola T; Quer J; Antón A
    Emerg Microbes Infect; 2022 Dec; 11(1):172-181. PubMed ID: 34842496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal.
    Borges V; Isidro J; Cortes-Martins H; Duarte S; Vieira L; Leite R; Gordo I; Caetano CP; Nunes B; Sá R; Oliveira A; Guiomar R; ; Gomes JP
    Emerg Microbes Infect; 2020 Dec; 9(1):2488-2496. PubMed ID: 33131453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    Microbiol Spectr; 2021 Sep; 9(1):e0003021. PubMed ID: 34346753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations.
    Wu J; Zhang HX; Zhang J
    Phys Chem Chem Phys; 2023 Jan; 25(3):2304-2319. PubMed ID: 36597957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding.
    Mannar D; Saville JW; Zhu X; Srivastava SS; Berezuk AM; Zhou S; Tuttle KS; Kim A; Li W; Dimitrov DS; Subramaniam S
    Cell Rep; 2021 Dec; 37(12):110156. PubMed ID: 34914928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 genome surveillance: A geographical landscape and mutational mapping of SARS-CoV-2 variants in central India over two years.
    Khairnar K; Tomar SS
    Virus Res; 2024 Jun; 344():199365. PubMed ID: 38527669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.
    Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
    mBio; 2021 Aug; 12(4):e0114021. PubMed ID: 34465019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants.
    Upadhyay V; Lucas A; Panja S; Miyauchi R; Mallela KMG
    J Biol Chem; 2021 Oct; 297(4):101208. PubMed ID: 34543625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
    Wang R; Chen J; Gao K; Wei GW
    Genomics; 2021 Jul; 113(4):2158-2170. PubMed ID: 34004284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Evolution and Biology of SARS-CoV-2 Variants.
    Telenti A; Hodcroft EB; Robertson DL
    Cold Spring Harb Perspect Med; 2022 May; 12(5):. PubMed ID: 35444005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 spike evolutionary behaviors; simulation of N501Y mutation outcomes in terms of immunogenicity and structural characteristic.
    Rostami N; Choupani E; Hernandez Y; Arab SS; Jazayeri SM; Gomari MM
    J Cell Biochem; 2022 Feb; 123(2):417-430. PubMed ID: 34783057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2.
    Laiton-Donato K; Franco-Muñoz C; Álvarez-Díaz DA; Ruiz-Moreno HA; Usme-Ciro JA; Prada DA; Reales-González J; Corchuelo S; Herrera-Sepúlveda MT; Naizaque J; Santamaría G; Rivera J; Rojas P; Ortiz JH; Cardona A; Malo D; Prieto-Alvarado F; Gómez FR; Wiesner M; Martínez MLO; Mercado-Reyes M
    Infect Genet Evol; 2021 Nov; 95():105038. PubMed ID: 34403832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion.
    Salleh MZ; Derrick JP; Deris ZZ
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan.
    Hirotsu Y; Omata M
    PLoS Pathog; 2021 Jun; 17(6):e1009619. PubMed ID: 34097716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of novel combinations of SARS-CoV-2 spike receptor binding domain variants in Senegal.
    Ahouidi AD; Rodgers MA; Padane A; Leye N; Olivo A; Mbow M; Mboup A; Diaw PA; Dia A; Harris B; Padane YAD; Lo G; Meyer TV; Diedhiou CK; Diagne D; Kane NCT; Cloherty G; Mboup S
    Sci Rep; 2021 Dec; 11(1):23644. PubMed ID: 34880295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
    Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.